Botulinum Toxin in Movement Disorders: An Update
Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological disorders. With respect to neurologic movement disor...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI AG
2021-01-01
|
| Serie: | Toxins |
| Soggetti: | |
| Accesso online: | https://www.mdpi.com/2072-6651/13/1/42 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|